Drug Trial Radar · NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
146
Planned (sponsor's estimate)
Start
May 6, 2022
Primary completion
Jun 30, 2027
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Mar 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Conditions
- B-cell Malignancy
- Non-Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Waldenström Macroglobulinemia
- Marginal Zone Lymphoma
- Follicular Lymphoma
- DLBCL Unclassifiable
- Richter's Transformation
Interventions
TacabrutidegDrug
Orally administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: From first dose of the study drug(s) to 30 days after the last dose or before initiation of a new anticancer therapy, whichever occurs first (up to approximately 3 years)
- Phase 1: Recommended Phase 2 dose (RP2D) of TacabrutidegTime frame: From the date of first dose of study drugs until RP2D is determined (up to approximately 37 weeks)
- Phase 1a: Maximum tolerated dose (MTD) of TacabrutidegTime frame: From the date of first dose of study drugs until RP2D is determined (up to approximately 37 weeks)
- Phase 2: Overall Response Rate (ORR) in participants with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)Time frame: Up to approximately 3 years
- Phase 2: ORR in participants with R/R Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Time frame: Up to approximately 3 years
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China · Recruiting
Anhui Provincial Hospital
Hefei, Anhui, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
Beijing Chao Yang Hospital,Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangdong Provincial Peoples Hospital Huifu Branch
Guangzhou, Guangdong, China · Recruiting
The Peoples Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China · Recruiting
Nanyang Central Hospital
Nanyang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, China · Recruiting
Jiangxi Province Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Affiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Qingdao Central Hospital
Qingdao, Shandong, China · Recruiting
Rui Jin Hospital Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, China · Recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Recruiting
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin Municipality, China · Recruiting
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine Branch Yuhang
Hangzhou, Zhejiang, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.